Vertex faces pressure from potential U.S. drug pricing reforms and tariffs. Click here to find out why VRTX stock is a Hold.
The FDA granted breakthrough therapy designation to a Vertex Pharmaceuticals kidney disease drug.
Vor Biopharma has rebounded from near-delisting by securing global rights (ex-China) to telitacicept, a promising autoimmune therapy. Click here to read more.
The auto industry is flashing warning lights on the state of the U.S. economy. Automakers' profits are getting squeezed by tariffs. A subprime auto lender recently collapsed, and some car retailers ...
Acumatica has announced the general availability of its 2025 R2 ERP Platform. The R2 release features new and updated enhancements that improve usability, ...
Our annual healthcare roundtable sizes up the risks and opportunities as public policy shifts. 16 stocks to buy now.
Ratings for Vertex (NASDAQ: VERX) were provided by 7 analysts in the past three months, showcasing a mix of bullish and ...
Ratings for Vertex Pharmaceuticals (NASDAQ: VRTX) were provided by 15 analysts in the past three months, showcasing a mix of ...
Zacks Investment Research on MSN
Vertex (VRTX) Is Considered a Good Investment by Brokers: Is That True?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a ...
The three-lap event, one of eight that day, was won by FC Pycroft in an unusual-looking Jaguar SS100, seeing off a small ...
Dana Miranda is a Certified Educator in Personal Finance, creator of the Healthy Rich newsletter and author of You Don't Need a Budget: Stop Worrying about Debt, Spend without Shame, and Manage Money ...
The Post welcomes letters up to 250 words on topics of general interest. Letters must include full name, home address, day and evening phone numbers, and may be edited for length, grammar and accuracy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback